VBI Vaccines (VBIV) Stock Rating Upgraded by ValuEngine

VBI Vaccines (NASDAQ:VBIV) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday.

Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Friday, September 28th. BMO Capital Markets cut their price objective on shares of VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, July 27th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $9.08.

VBIV traded up $0.21 during trading on Thursday, hitting $1.94. The company had a trading volume of 358,591 shares, compared to its average volume of 222,125. VBI Vaccines has a one year low of $1.64 and a one year high of $5.10. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 0.14.

In other VBI Vaccines news, CEO Jeff Baxter purchased 13,500 shares of the business’s stock in a transaction on Friday, August 3rd. The shares were purchased at an average cost of $2.01 per share, with a total value of $27,135.00. Following the transaction, the chief executive officer now directly owns 224,905 shares of the company’s stock, valued at approximately $452,059.05. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 23,600 shares of company stock worth $46,788 over the last three months. Insiders own 54.50% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Russell Investments Group Ltd. lifted its position in VBI Vaccines by 7.3% during the 1st quarter. Russell Investments Group Ltd. now owns 491,449 shares of the biopharmaceutical company’s stock worth $1,720,000 after buying an additional 33,588 shares in the last quarter. DRW Securities LLC acquired a new position in VBI Vaccines in the 2nd quarter valued at about $126,000. Alpine Global Management LLC bought a new stake in VBI Vaccines in the 2nd quarter valued at about $222,000. Dimensional Fund Advisors LP bought a new stake in VBI Vaccines in the 2nd quarter valued at about $223,000. Finally, LMR Partners LLP bought a new stake in VBI Vaccines in the 2nd quarter valued at about $233,000. 48.00% of the stock is currently owned by hedge funds and other institutional investors.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Read More: Return on Equity (ROE)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply